# Epi-GERD Study: Epidemiological Evaluation in Patients With Gastro-Esophageal Reflux Disease (GERD)

> **NCT04094402** · — · UNKNOWN · sponsor: **Scandinavia Pharma** · enrollment: 1500 (estimated)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **OTHER:** None. It is an observational study

## Key facts

- **NCT ID:** NCT04094402
- **Lead sponsor:** Scandinavia Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-04
- **Primary completion:** 2023-12
- **Final completion:** 2024-07
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2019-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04094402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04094402, "Epi-GERD Study: Epidemiological Evaluation in Patients With Gastro-Esophageal Reflux Disease (GERD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04094402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*